Details

Autor(en) / Beteiligte

• Weulersse, Marianne
• Asrir, Assia
• Pichler, Andrea C.
• Lemaitre, Lea
• Braun, Matthias
• Carrié, Nadège
• Joubert, Marie-Véronique
• Le Moine, Marie
• Do Souto, Laura
• Gaud, Guillaume
• Das, Indrajit
• Brauns, Elisa
• Scarlata, Clara M.
• Morandi, Elena
• Sundarrajan, Ashmitha
• Cuisinier, Marine
• Buisson, Laure
• Maheo, Sabrina
• Kassem, Sahar
• Agesta, Arantxa
• Pérès, Michaël
• Verhoeyen, Els
• Martinez, Alejandra
• Mazieres, Julien
• Dupré, Loïc
• Gossye, Thomas
• Pancaldi, Vera
• Guillerey, Camille
• Ayyoub, Maha
• Dejean, Anne S.
• Saoudi, Abdelhadi
• Goriely, Stanislas
• Avet-Loiseau, Hervé
• Bald, Tobias
• Smyth, Mark J.
• Martinet, Ludovic

Titel

Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8+ T Cell Anti-tumor Functions and Limits the Efficacy of Cancer Immunotherapy

Ist Teil von

• Immunity (Cambridge, Mass.), 2020-10, Vol.53 (4), p.824-839.e10

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• CD8+ T cells within the tumor microenvironment (TME) are exposed to various signals that ultimately determine functional outcomes. Here, we examined the role of the co-activating receptor CD226 (DNAM-1) in CD8+ T cell function. The absence of CD226 expression identified a subset of dysfunctional CD8+ T cells present in peripheral blood of healthy individuals. These cells exhibited reduced LFA-1 activation, altered TCR signaling, and a distinct transcriptomic program upon stimulation. CD226neg CD8+ T cells accumulated in human and mouse tumors of diverse origin through an antigen-specific mechanism involving the transcriptional regulator Eomesodermin (Eomes). Despite similar expression of co-inhibitory receptors, CD8+ tumor-infiltrating lymphocyte failed to respond to anti-PD-1 in the absence of CD226. Immune checkpoint blockade efficacy was hampered in Cd226−/− mice. Anti-CD137 (4-1BB) agonists also stimulated Eomes-dependent CD226 loss that limited the anti-tumor efficacy of this treatment. Thus, CD226 loss restrains CD8+ T cell function and limits the efficacy of cancer immunotherapy. [Display omitted] •TCR signaling and CD8+ T effector program are altered by the absence of CD226•Dysfunctional CD226neg CD8+ TILs accumulate in human and mouse tumors•Eomes overexpression is involved in CD226 loss by CD8+ TILs•CD226 loss limits the efficacy of immune checkpoint blockade and CD137 agonists. Through complementary approaches, involving cancer patients’ samples and relevant mouse tumor models, Weulersse et al. reveal that CD8+ T cells in the tumor microenvironment lose expression of the activating receptor CD226 (DNAM-1) in a manner that is Eomes dependent. CD226 loss restrains CD8+ T cell function and limits the efficacy of cancer immunotherapy.